Selective modulation of thyroid hormone receptor action

Thyroid hormones have some actions that might be useful therapeutically, but others that are deleterious. Potential therapeutically useful actions include those to induce weight loss and lower plasma cholesterol levels. Potential deleterious actions are those on the heart to induce tachycardia and arrhythmia, on bone to decrease mineral density, and on muscle to induce wasting. There have been successes in selectively modulating the actions of other classes of hormones through various means, including the use of pharmaceuticals that have enhanced affinities for certain receptor isoforms. Thus, there is reason to pursue selective modulation of thyroid hormone receptor (TR) function, and several agents have been shown to have some beta -selective, hepatic selective and/or cardiac sparring activities, although development of these was largely not based on detailed understanding of mechanisms for the specificity. The possibility of selectively targeting the TR beta was suggested by the findings that there are alpha- and beta -TR forms and that the TR alpha -forms may preferentially regulate the heart rate, whereas many other actions of these hormones are mediated by the TR beta. We determined X-ray crystal structures of the TR alpha and TR beta ligand-binding domains (LBDs) complexed with the thyroid hormone analog 3,5,3'-triiodithyroacetic acid (Triac). The data suggested that a single amino acid difference in the ligand-binding cavities of the two receptors could affect hydrogen bonding in the receptor region, where the ligand's 1-position substituent fits and might be exploited to generate beta -selective ligands. The compound GC-1, with oxoacetate in the 1-position instead of acetate as in Triac, exhibited TR beta -selective binding and actions in cultured cells. An X-ray crystal structure of the GC-1-TR beta LED complex suggests that the oxoacetate does participate in a network of hydrogen bonding in the TR LED polar pocket. GC-1 displayed actions in tadpoles that were TR beta -selective. When administered to mice, GC-1 was as effective in lowering plasma cholesterol levels as T-3, and was more effective than T-3 in lowering plasma triglyceride levels. At these doses, GC-1 did not increase the heart rate. GC-1 was also less active than T-3 in modulating activities of several other cardiac parameters, and especially a cardiac pacemaker channel such as HCN-2, which may participate in regulation of the heart rate. GC-1 showed intermediate activity in suppressing plasma thyroid stimulating hormone (TSH) levels. The tissue/plasma ratio for GC-1 in heart was also less than for the liver. These data suggest that compounds can be generated that are TR-selective and that compounds with this property and/or that exhibit selective uptake, might have clinical utility as selective TR modulators. (C) 2001 Elsevier Science Ltd. All rights reserved.